Advertisement
Advertisement
Hong Kong Business Report
Get more with myNEWS
A personalised news feed of stories that matter to you
Learn more
Joseph Lun, director. Photo: Handout

OTC medication Weisen-U targets multiple gastrointestinal issues

  • The formulation and production techniques of the Weisen-U drug are constantly refined to meet regulatory standards
Supported by:Discovery Reports

Country Business Reports interviews and articles by Discovery Reports

Hectic lifestyles, coupled with unbalanced diets, take a toll on gastrointestinal health and if left unchecked, could lead to stomach problems.

Aiming to improve the quality of life of those affected, and looking to provide better access to safe and effective medication, Hong Kong’s Kin Fung Weisen-U created Weisen-U, an over-the-counter (OTC) drug developed to address gastrointestinal and stomach issues.

Weisen-U has almost 60 years of history. First developed in the 1960s, Weisen-U relieves discomfort caused by indigestion, heartburn, lack of appetite, hyperacidity, and more. Formulated as a unique dual-layer tablet, Weisen-U’s outer antacid core neutralises excessive gastric acid. Its inner layer reacts and facilitates the rapid healing of damaged parts of the stomach.

“From the 1960s to 1980s, Weisen-U became the trusted OTC gastrointestinal drug in Hong Kong, Macau, Singapore, Malaysia and mainland China. By the 1990s, Chinese communities in Australia, Canada, the United States and Europe made Weisen-U a household name,” said director Joseph Lun.

Committed to delivering the best-quality products with the highest efficacy, Kin Fung Weisen-U has constantly refined Weisen-U’s formulation and production techniques to meet regulatory standards.

“Our world is fast changing, and everyone must adapt to the latest situation. If you don’t, you fall behind,” Lun said.

Applying its extensive knowledge from Weisen-U’s success, the company developed Weisen-U Enzyme, an intestinal health solution containing powerful biodiastase that promotes improved digestion of fats, carbohydrates, protein and cellulose.

Kin Fung Weisen-U plans to further expand its product line and sees collaborations with universities and research institutes as key initiatives that can help with its goal. As it broadens its portfolio, Kin Fung Weisen-U is also setting its sights on growing its reach.

The company works with sole agents in specific markets in building distribution networks and key customer connections. It will go through the same route this year as it launches its products in Asean while aspiring to add more Asian countries to its distribution network.

Post